CA2729767A1 - Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same - Google Patents
Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same Download PDFInfo
- Publication number
- CA2729767A1 CA2729767A1 CA2729767A CA2729767A CA2729767A1 CA 2729767 A1 CA2729767 A1 CA 2729767A1 CA 2729767 A CA2729767 A CA 2729767A CA 2729767 A CA2729767 A CA 2729767A CA 2729767 A1 CA2729767 A1 CA 2729767A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- compound
- aryl
- alkylaryl
- residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 151
- 238000000034 method Methods 0.000 title claims description 38
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 19
- 125000003118 aryl group Chemical group 0.000 claims abstract description 51
- 125000002877 alkyl aryl group Chemical group 0.000 claims abstract description 44
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 35
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 31
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 30
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 27
- 125000000392 cycloalkenyl group Chemical group 0.000 claims abstract description 25
- 150000004820 halides Chemical class 0.000 claims abstract description 24
- 150000007942 carboxylates Chemical group 0.000 claims abstract description 21
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 17
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims abstract description 15
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims abstract description 12
- 125000005843 halogen group Chemical group 0.000 claims abstract description 12
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims abstract description 11
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims abstract description 9
- 125000003860 C1-C20 alkoxy group Chemical group 0.000 claims abstract description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 8
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 8
- 101710091951 Glycerol-3-phosphate acyltransferase Proteins 0.000 claims description 73
- 230000004580 weight loss Effects 0.000 claims description 54
- 230000000694 effects Effects 0.000 claims description 33
- 230000001965 increasing effect Effects 0.000 claims description 26
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 238000007254 oxidation reaction Methods 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 14
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 13
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 12
- 239000000194 fatty acid Substances 0.000 claims description 12
- 229930195729 fatty acid Natural products 0.000 claims description 12
- 150000004665 fatty acids Chemical class 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 230000003647 oxidation Effects 0.000 claims description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 238000006467 substitution reaction Methods 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000003107 substituted aryl group Chemical group 0.000 claims description 5
- 229910018828 PO3H2 Inorganic materials 0.000 claims description 4
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 4
- 150000001735 carboxylic acids Chemical group 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical group [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 abstract description 6
- WNFXEGWGYFRRJC-UHFFFAOYSA-N 2-(nonylsulfonylamino)benzoic acid Chemical compound CCCCCCCCCS(=O)(=O)NC1=CC=CC=C1C(O)=O WNFXEGWGYFRRJC-UHFFFAOYSA-N 0.000 description 125
- 241000699670 Mus sp. Species 0.000 description 106
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 76
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 66
- 239000003981 vehicle Substances 0.000 description 63
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 56
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 54
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 49
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 49
- 239000000243 solution Substances 0.000 description 44
- 238000006243 chemical reaction Methods 0.000 description 42
- 238000005160 1H NMR spectroscopy Methods 0.000 description 41
- 241001465754 Metazoa Species 0.000 description 41
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 238000005481 NMR spectroscopy Methods 0.000 description 39
- 230000015572 biosynthetic process Effects 0.000 description 39
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 38
- 238000003786 synthesis reaction Methods 0.000 description 37
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 36
- 235000012631 food intake Nutrition 0.000 description 33
- 230000014509 gene expression Effects 0.000 description 31
- 230000002829 reductive effect Effects 0.000 description 30
- 235000019439 ethyl acetate Nutrition 0.000 description 28
- 230000009467 reduction Effects 0.000 description 28
- 229910001868 water Inorganic materials 0.000 description 28
- 238000000692 Student's t-test Methods 0.000 description 26
- 238000012353 t test Methods 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 239000000047 product Substances 0.000 description 22
- 238000000540 analysis of variance Methods 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 239000000203 mixture Substances 0.000 description 19
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 18
- 230000005764 inhibitory process Effects 0.000 description 17
- 230000037406 food intake Effects 0.000 description 16
- 238000004809 thin layer chromatography Methods 0.000 description 16
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 14
- 238000010992 reflux Methods 0.000 description 14
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 13
- 208000008589 Obesity Diseases 0.000 description 12
- 230000001684 chronic effect Effects 0.000 description 12
- 235000020824 obesity Nutrition 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 108010018763 Biotin carboxylase Proteins 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 239000003925 fat Substances 0.000 description 11
- 239000010410 layer Substances 0.000 description 11
- 229940124530 sulfonamide Drugs 0.000 description 11
- 150000003456 sulfonamides Chemical class 0.000 description 11
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 210000001789 adipocyte Anatomy 0.000 description 10
- 235000019197 fats Nutrition 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 108090000189 Neuropeptides Proteins 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 230000003520 lipogenic effect Effects 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 101710151321 Melanostatin Proteins 0.000 description 8
- 102400000064 Neuropeptide Y Human genes 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000004891 conditioned taste aversion Effects 0.000 description 8
- 238000003818 flash chromatography Methods 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 8
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 8
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 8
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- -1 unsaturated alkyl radical Chemical class 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000003797 Neuropeptides Human genes 0.000 description 7
- 102000001708 Protein Isoforms Human genes 0.000 description 7
- 108010029485 Protein Isoforms Proteins 0.000 description 7
- 210000000593 adipose tissue white Anatomy 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 230000002267 hypothalamic effect Effects 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 7
- 102100039164 Acetyl-CoA carboxylase 1 Human genes 0.000 description 6
- 102000054930 Agouti-Related Human genes 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 102000008219 Uncoupling Protein 2 Human genes 0.000 description 6
- 108010021111 Uncoupling Protein 2 Proteins 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 230000002438 mitochondrial effect Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 229940081974 saccharin Drugs 0.000 description 6
- 235000019204 saccharin Nutrition 0.000 description 6
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 5
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 5
- 229910014033 C-OH Inorganic materials 0.000 description 5
- 229910014570 C—OH Inorganic materials 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 4
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 4
- 101710127426 Agouti-related protein Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 206010019708 Hepatic steatosis Diseases 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 4
- 239000000683 Pro-Opiomelanocortin Substances 0.000 description 4
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 238000007707 calorimetry Methods 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000001956 orexigenic effect Effects 0.000 description 4
- MNBKLUUYKPBKDU-BBECNAHFSA-N palmitoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MNBKLUUYKPBKDU-BBECNAHFSA-N 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 235000018770 reduced food intake Nutrition 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 4
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000034570 NR1 subfamily Human genes 0.000 description 3
- 108020001305 NR1 subfamily Proteins 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 125000004422 alkyl sulphonamide group Chemical group 0.000 description 3
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 3
- 230000002891 anorexigenic effect Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000031709 bromination Effects 0.000 description 3
- 238000005893 bromination reaction Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 150000001982 diacylglycerols Chemical class 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 150000002313 glycerolipids Chemical class 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000000185 intracerebroventricular administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 238000009790 rate-determining step (RDS) Methods 0.000 description 3
- 238000012755 real-time RT-PCR analysis Methods 0.000 description 3
- 231100000272 reduced body weight Toxicity 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 230000007863 steatosis Effects 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 235000011149 sulphuric acid Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 241000220479 Acacia Species 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 241001631457 Cannula Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 101000680845 Luffa aegyptiaca Ribosome-inactivating protein luffin P1 Proteins 0.000 description 2
- LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- WYJXFFFWDRMGRG-UHFFFAOYSA-M [Na+].BrN1C(=O)NC(=O)[N-]C1=O Chemical compound [Na+].BrN1C(=O)NC(=O)[N-]C1=O WYJXFFFWDRMGRG-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- 150000001499 aryl bromides Chemical class 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 150000001559 benzoic acids Chemical class 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000004136 fatty acid synthesis Effects 0.000 description 2
- 150000002185 fatty acyl-CoAs Chemical class 0.000 description 2
- 239000000446 fuel Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- FFHOZAXLIFAWOS-UHFFFAOYSA-N n-cyclohexyl-n-ethyl-3,4-dimethoxybenzenesulfonamide Chemical compound C=1C=C(OC)C(OC)=CC=1S(=O)(=O)N(CC)C1CCCCC1 FFHOZAXLIFAWOS-UHFFFAOYSA-N 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 150000003009 phosphonic acids Chemical class 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- GVEZIHKRYBHEFX-MNOVXSKESA-N 13C-Cerulenin Natural products CC=CCC=CCCC(=O)[C@H]1O[C@@H]1C(N)=O GVEZIHKRYBHEFX-MNOVXSKESA-N 0.000 description 1
- MSTYKDCUOYZXAK-UHFFFAOYSA-N 2-(2-phenylethylsulfonylamino)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1NS(=O)(=O)CCC1=CC=CC=C1 MSTYKDCUOYZXAK-UHFFFAOYSA-N 0.000 description 1
- KIAHUXDVSURYKM-UHFFFAOYSA-N 2-(benzenesulfonamido)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1NS(=O)(=O)C1=CC=CC=C1 KIAHUXDVSURYKM-UHFFFAOYSA-N 0.000 description 1
- WGEQJQSCWKQOOF-UHFFFAOYSA-N 2-(benzylsulfonylamino)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1NS(=O)(=O)CC1=CC=CC=C1 WGEQJQSCWKQOOF-UHFFFAOYSA-N 0.000 description 1
- QSLMPDKYTNEMFQ-UHFFFAOYSA-N 2-(bromomethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CBr QSLMPDKYTNEMFQ-UHFFFAOYSA-N 0.000 description 1
- GZSCLHZCZQDVNG-UHFFFAOYSA-N 2-(hexadecylsulfonylamino)benzoic acid Chemical compound CCCCCCCCCCCCCCCCS(=O)(=O)NC1=CC=CC=C1C(O)=O GZSCLHZCZQDVNG-UHFFFAOYSA-N 0.000 description 1
- VESLFCBOKMWCRG-UHFFFAOYSA-N 2-(methanesulfonamido)benzoic acid Chemical compound CS(=O)(=O)NC1=CC=CC=C1C(O)=O VESLFCBOKMWCRG-UHFFFAOYSA-N 0.000 description 1
- RHDJRAWRTFGBOB-UHFFFAOYSA-N 2-(tetradecylsulfonylamino)benzoic acid Chemical compound CCCCCCCCCCCCCCS(=O)(=O)NC1=CC=CC=C1C(O)=O RHDJRAWRTFGBOB-UHFFFAOYSA-N 0.000 description 1
- OWHRRXDJMFQNDI-UHFFFAOYSA-N 2-[(4-chlorophenyl)sulfonylamino]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1NS(=O)(=O)C1=CC=C(Cl)C=C1 OWHRRXDJMFQNDI-UHFFFAOYSA-N 0.000 description 1
- AMJHGKMFDUBZCT-UHFFFAOYSA-N 2-[(nonylsulfonylamino)methyl]benzoic acid Chemical compound CCCCCCCCCS(=O)(=O)NCC1=CC=CC=C1C(O)=O AMJHGKMFDUBZCT-UHFFFAOYSA-N 0.000 description 1
- FHSKLWOLCLADJG-UHFFFAOYSA-N 2-[(pentylsulfonylamino)methyl]benzoic acid Chemical compound CCCCCS(=O)(=O)NCC1=CC=CC=C1C(O)=O FHSKLWOLCLADJG-UHFFFAOYSA-N 0.000 description 1
- LKFNLHZZPHHFEC-UHFFFAOYSA-N 2-phenylethanesulfonyl chloride Chemical compound ClS(=O)(=O)CCC1=CC=CC=C1 LKFNLHZZPHHFEC-UHFFFAOYSA-N 0.000 description 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
- NMCWIAAUCFVHEQ-UHFFFAOYSA-N 3-(2-phenylethylsulfonylamino)benzoic acid Chemical compound OC(=O)C1=CC=CC(NS(=O)(=O)CCC=2C=CC=CC=2)=C1 NMCWIAAUCFVHEQ-UHFFFAOYSA-N 0.000 description 1
- RELBUFSHELNQKC-UHFFFAOYSA-N 3-(benzenesulfonamido)benzoic acid Chemical compound OC(=O)C1=CC=CC(NS(=O)(=O)C=2C=CC=CC=2)=C1 RELBUFSHELNQKC-UHFFFAOYSA-N 0.000 description 1
- QIKUOKKSPSEHEY-UHFFFAOYSA-N 3-(benzylsulfonylamino)benzoic acid Chemical compound OC(=O)C1=CC=CC(NS(=O)(=O)CC=2C=CC=CC=2)=C1 QIKUOKKSPSEHEY-UHFFFAOYSA-N 0.000 description 1
- JZBBGWTTWNAIAX-UHFFFAOYSA-N 3-(nonylsulfonylamino)benzoic acid Chemical compound CCCCCCCCCS(=O)(=O)NC1=CC=CC(C(O)=O)=C1 JZBBGWTTWNAIAX-UHFFFAOYSA-N 0.000 description 1
- QLZXSYFEOSMCSB-UHFFFAOYSA-N 3-[(4-chlorophenyl)sulfonylamino]benzoic acid Chemical compound OC(=O)C1=CC=CC(NS(=O)(=O)C=2C=CC(Cl)=CC=2)=C1 QLZXSYFEOSMCSB-UHFFFAOYSA-N 0.000 description 1
- LQSKFIJPOTWVSS-UHFFFAOYSA-N 3-[(nonylsulfonylamino)methyl]benzoic acid Chemical compound CCCCCCCCCS(=O)(=O)NCC1=CC=CC(C(O)=O)=C1 LQSKFIJPOTWVSS-UHFFFAOYSA-N 0.000 description 1
- OCWGPJGAKUONSD-UHFFFAOYSA-N 3-[(pentylsulfonylamino)methyl]benzoic acid Chemical compound CCCCCS(=O)(=O)NCC1=CC=CC(C(O)=O)=C1 OCWGPJGAKUONSD-UHFFFAOYSA-N 0.000 description 1
- LBCHJLKLZXSALP-UHFFFAOYSA-N 4-(2-phenylethylsulfonylamino)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NS(=O)(=O)CCC1=CC=CC=C1 LBCHJLKLZXSALP-UHFFFAOYSA-N 0.000 description 1
- YAGOYAVZOJQMRT-UHFFFAOYSA-N 4-(benzenesulfonamido)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NS(=O)(=O)C1=CC=CC=C1 YAGOYAVZOJQMRT-UHFFFAOYSA-N 0.000 description 1
- ZOFLWJXPXAHZLI-UHFFFAOYSA-N 4-(benzylsulfonylamino)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NS(=O)(=O)CC1=CC=CC=C1 ZOFLWJXPXAHZLI-UHFFFAOYSA-N 0.000 description 1
- NIVLVNDEPULRIG-UHFFFAOYSA-N 4-(nonylsulfonylamino)benzoic acid Chemical compound CCCCCCCCCS(=O)(=O)NC1=CC=C(C(O)=O)C=C1 NIVLVNDEPULRIG-UHFFFAOYSA-N 0.000 description 1
- SKLUWKYNZNXSLX-UHFFFAOYSA-N 4-Acetamidobenzaldehyde Chemical class CC(=O)NC1=CC=C(C=O)C=C1 SKLUWKYNZNXSLX-UHFFFAOYSA-N 0.000 description 1
- IBRLPMYEEPGIAK-UHFFFAOYSA-N 4-[(4-chlorophenyl)sulfonylamino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NS(=O)(=O)C1=CC=C(Cl)C=C1 IBRLPMYEEPGIAK-UHFFFAOYSA-N 0.000 description 1
- QFRHQRDJXCDHFE-UHFFFAOYSA-N 4-[(nonylsulfonylamino)methyl]benzoic acid Chemical compound CCCCCCCCCS(=O)(=O)NCC1=CC=C(C(O)=O)C=C1 QFRHQRDJXCDHFE-UHFFFAOYSA-N 0.000 description 1
- QVLNOHYKDQDFDI-UHFFFAOYSA-N 4-[(pentylsulfonylamino)methyl]benzoic acid Chemical compound CCCCCS(=O)(=O)NCC1=CC=C(C(O)=O)C=C1 QVLNOHYKDQDFDI-UHFFFAOYSA-N 0.000 description 1
- VCWLZDVWHQVAJU-UHFFFAOYSA-N 4-methylidene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid Chemical compound CCCCCCCCC1OC(=O)C(=C)C1C(O)=O VCWLZDVWHQVAJU-UHFFFAOYSA-N 0.000 description 1
- UPTVYMLQUVFSSI-UHFFFAOYSA-N 5-chloro-2-(nonylsulfonylamino)benzoic acid Chemical compound CCCCCCCCCS(=O)(=O)NC1=CC=C(Cl)C=C1C(O)=O UPTVYMLQUVFSSI-UHFFFAOYSA-N 0.000 description 1
- KISWNPYVOWDIEG-UHFFFAOYSA-N 5-fluoro-2-(octylsulfonylamino)benzoic acid Chemical compound CCCCCCCCS(=O)(=O)NC1=CC=C(F)C=C1C(O)=O KISWNPYVOWDIEG-UHFFFAOYSA-N 0.000 description 1
- VDGJSDSBVHSIHV-UHFFFAOYSA-N 5-hydroxy-2-(octylsulfonylamino)benzoic acid Chemical compound CCCCCCCCS(=O)(=O)NC1=CC=C(O)C=C1C(O)=O VDGJSDSBVHSIHV-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 101710199726 Glycerol-3-phosphate acyltransferase 1 Proteins 0.000 description 1
- 102100024008 Glycerol-3-phosphate acyltransferase 1, mitochondrial Human genes 0.000 description 1
- 102100024015 Glycerol-3-phosphate acyltransferase 2, mitochondrial Human genes 0.000 description 1
- 102100024017 Glycerol-3-phosphate acyltransferase 3 Human genes 0.000 description 1
- 102100025376 Glycerol-3-phosphate acyltransferase 4 Human genes 0.000 description 1
- 101710199766 Glycerol-3-phosphate acyltransferase 4 Proteins 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 101000904268 Homo sapiens Glycerol-3-phosphate acyltransferase 1, mitochondrial Proteins 0.000 description 1
- 101000904251 Homo sapiens Glycerol-3-phosphate acyltransferase 2, mitochondrial Proteins 0.000 description 1
- 101000904259 Homo sapiens Glycerol-3-phosphate acyltransferase 3 Proteins 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 238000005654 Michaelis-Arbuzov synthesis reaction Methods 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101000755720 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) Palmitoyltransferase akr1 Proteins 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- CTQNLXWEQXSGSA-YBHXOQPNSA-N [(4s)-4-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylidenepropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoyl]amino]-5-[[2-[[(2s)-1-[(2s)-2-[[2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]acetyl]amin Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@@H](N)CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)OC(=O)CC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)C=S)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)OC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](N)CS)CC1=CC=CC=C1 CTQNLXWEQXSGSA-YBHXOQPNSA-N 0.000 description 1
- WZOKYUNRNUSPPJ-UHFFFAOYSA-N [2-(nonylsulfonylamino)phenyl]methylphosphonic acid Chemical compound CCCCCCCCCS(=O)(=O)NC1=CC=CC=C1CP(O)(O)=O WZOKYUNRNUSPPJ-UHFFFAOYSA-N 0.000 description 1
- SYEDOWIBRHDUDM-UHFFFAOYSA-N [2-(octylsulfonylamino)phenyl]phosphonic acid Chemical compound CCCCCCCCS(=O)(=O)NC1=CC=CC=C1P(O)(O)=O SYEDOWIBRHDUDM-UHFFFAOYSA-N 0.000 description 1
- NMRNAOQBMIHIPQ-UHFFFAOYSA-N [2-(pentylsulfonylamino)phenyl]methylphosphonic acid Chemical compound CCCCCS(=O)(=O)NC1=CC=CC=C1CP(O)(O)=O NMRNAOQBMIHIPQ-UHFFFAOYSA-N 0.000 description 1
- VJQDYPNXUZQPPR-UHFFFAOYSA-N [3-(nonylsulfonylamino)phenyl]methylphosphonic acid Chemical compound CCCCCCCCCS(=O)(=O)NC1=CC=CC(CP(O)(O)=O)=C1 VJQDYPNXUZQPPR-UHFFFAOYSA-N 0.000 description 1
- JBPYJKPNWHUZRE-UHFFFAOYSA-N [3-(octylsulfonylamino)phenyl]phosphonic acid Chemical compound CCCCCCCCS(=O)(=O)NC1=CC=CC(P(O)(O)=O)=C1 JBPYJKPNWHUZRE-UHFFFAOYSA-N 0.000 description 1
- YNJHMALBXAGSEX-UHFFFAOYSA-N [3-(pentylsulfonylamino)phenyl]methylphosphonic acid Chemical compound CCCCCS(=O)(=O)NC1=CC=CC(CP(O)(O)=O)=C1 YNJHMALBXAGSEX-UHFFFAOYSA-N 0.000 description 1
- MHOQASIFZSEHKR-UHFFFAOYSA-N [4-(nonylsulfonylamino)phenyl]methylphosphonic acid Chemical compound CCCCCCCCCS(=O)(=O)NC1=CC=C(CP(O)(O)=O)C=C1 MHOQASIFZSEHKR-UHFFFAOYSA-N 0.000 description 1
- GNUONXJCYRXQHK-UHFFFAOYSA-N [4-(octylsulfonylamino)phenyl]phosphonic acid Chemical compound CCCCCCCCS(=O)(=O)NC1=CC=C(P(O)(O)=O)C=C1 GNUONXJCYRXQHK-UHFFFAOYSA-N 0.000 description 1
- IBMGKQVESDYZEL-UHFFFAOYSA-N [4-(pentylsulfonylamino)phenyl]methylphosphonic acid Chemical compound CCCCCS(=O)(=O)NC1=CC=C(CP(O)(O)=O)C=C1 IBMGKQVESDYZEL-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 229940124693 antiobesity therapeutics Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 125000004421 aryl sulphonamide group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- GVEZIHKRYBHEFX-UHFFFAOYSA-N caerulein A Natural products CC=CCC=CCCC(=O)C1OC1C(N)=O GVEZIHKRYBHEFX-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- GVEZIHKRYBHEFX-NQQPLRFYSA-N cerulenin Chemical compound C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O GVEZIHKRYBHEFX-NQQPLRFYSA-N 0.000 description 1
- 229950005984 cerulenin Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000001729 effect on metabolism Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000014105 formulated food Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 231100000437 hepatocellular injury Toxicity 0.000 description 1
- IPCSVZSSVZVIGE-VPMSBSONSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCC[14C](O)=O IPCSVZSSVZVIGE-VPMSBSONSA-N 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 235000021070 high sugar diet Nutrition 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000013190 lipid storage Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000006140 methanolysis reaction Methods 0.000 description 1
- WVWZECQNFWFVFW-UHFFFAOYSA-N methyl 2-methylbenzoate Chemical class COC(=O)C1=CC=CC=C1C WVWZECQNFWFVFW-UHFFFAOYSA-N 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- AJOTWPQTESRFCQ-UHFFFAOYSA-N nonane-1-sulfonyl chloride Chemical compound CCCCCCCCCS(Cl)(=O)=O AJOTWPQTESRFCQ-UHFFFAOYSA-N 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- WIVNTNLDTMNDNO-UHFFFAOYSA-N octane-1-sulfonyl chloride Chemical compound CCCCCCCCS(Cl)(=O)=O WIVNTNLDTMNDNO-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical group CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- PWQOZRPSDQKNPW-UHFFFAOYSA-N pentane-1-sulfonyl chloride Chemical compound CCCCCS(Cl)(=O)=O PWQOZRPSDQKNPW-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000009955 peripheral mechanism Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- OAHKWDDSKCRNFE-UHFFFAOYSA-N phenylmethanesulfonyl chloride Chemical compound ClS(=O)(=O)CC1=CC=CC=C1 OAHKWDDSKCRNFE-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000003322 phosphorimaging Methods 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- QAQREVBBADEHPA-IEXPHMLFSA-N propionyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 QAQREVBBADEHPA-IEXPHMLFSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 108010048412 somatotropin (177-191) Proteins 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000004992 toluidines Chemical class 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3834—Aromatic acids (P-C aromatic linkage)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3882—Arylalkanephosphonic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12957808P | 2008-07-07 | 2008-07-07 | |
| US61/129,578 | 2008-07-07 | ||
| PCT/US2009/049744 WO2010005922A1 (en) | 2008-07-07 | 2009-07-07 | Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2729767A1 true CA2729767A1 (en) | 2010-01-14 |
Family
ID=41507395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2729767A Abandoned CA2729767A1 (en) | 2008-07-07 | 2009-07-07 | Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20120083471A1 (enExample) |
| EP (1) | EP2303013A1 (enExample) |
| JP (1) | JP2011527345A (enExample) |
| CN (1) | CN102395270B (enExample) |
| CA (1) | CA2729767A1 (enExample) |
| MX (1) | MX2011000051A (enExample) |
| WO (1) | WO2010005922A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| JP2013532688A (ja) | 2010-07-26 | 2013-08-19 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃｙｐ１７阻害剤として有用なスルホンアミド化合物 |
| US8450367B2 (en) * | 2010-12-16 | 2013-05-28 | Allergan, Inc. | Sulfur derivatives as chemokine receptor modulators |
| JPWO2012124744A1 (ja) * | 2011-03-14 | 2014-07-24 | 大正製薬株式会社 | 含窒素縮合複素環化合物 |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013155528A2 (en) * | 2012-04-13 | 2013-10-17 | Fasgen, Inc. | Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels |
| EP3083614B1 (en) | 2013-12-18 | 2020-01-15 | GlaxoSmithKline Intellectual Property Development Limited | Nrf2 regulators |
| US9701627B2 (en) * | 2014-06-16 | 2017-07-11 | University Of Maryland, Baltimore | LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders |
| WO2016172218A1 (en) * | 2015-04-20 | 2016-10-27 | The Regents Of The University Of Michigan | Small molecule inhibitors of mcl-1 and uses thereof |
| PE20180799A1 (es) | 2015-06-15 | 2018-05-09 | Glaxosmithkline Ip Dev Ltd | Reguladores de nrf2 |
| ES2834490T3 (es) | 2015-06-15 | 2021-06-17 | Glaxosmithkline Ip Dev Ltd | Reguladores de NRF2 |
| WO2017060854A1 (en) | 2015-10-06 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as nrf2 regulators |
| WO2019165232A1 (en) * | 2018-02-23 | 2019-08-29 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibitors of phospholipid synthesis and methods of use |
| WO2021035031A1 (en) * | 2019-08-21 | 2021-02-25 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibitors of phospholipid synthesis and methods of use |
| TW202444703A (zh) | 2021-09-14 | 2024-11-16 | 美商美國禮來大藥廠 | Sstr4促效劑鹽 |
| WO2025140544A1 (zh) * | 2023-12-28 | 2025-07-03 | 南京瑞初医药有限公司 | Gsdmd抑制剂及其用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2531367A (en) * | 1947-07-15 | 1950-11-21 | Sharp & Dohme Inc | N-(substituted sulfonyl)-aminobenzoic acids |
| DE2611705A1 (de) * | 1976-03-18 | 1977-09-22 | Josef Dipl Chem Dr Rer N Klosa | N-5-(nitrofurfuryliden-)-1-amino- hydantoin enthaltende kristalloesungsmittel |
| DE3000377A1 (de) * | 1980-01-07 | 1981-07-09 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel |
| FR2509305B1 (fr) * | 1981-07-08 | 1986-04-18 | Sanofi Sa | Benzamides, procede pour leur preparation et compositions pharmaceutiques les renfermant |
| AU567140B2 (en) * | 1984-01-06 | 1987-11-12 | Shionogi & Co., Ltd. | Sulphonamido-benzamide derivatives |
| DE4003054A1 (de) * | 1990-02-02 | 1991-08-08 | Hoechst Ag | Verwendung von benzylphosphonsaeurederivaten zur behandlung von durch viren verursachte krankheiten |
| DE69023336T2 (de) * | 1990-08-22 | 1996-05-30 | Agfa Gevaert Nv | Partikeltonermaterial. |
| JP3577336B2 (ja) * | 1994-04-26 | 2004-10-13 | 三井化学株式会社 | 感熱記録材料 |
| US5981575A (en) * | 1996-11-15 | 1999-11-09 | Johns Hopkins University, The | Inhibition of fatty acid synthase as a means to reduce adipocyte mass |
| US20030124187A1 (en) * | 1997-02-14 | 2003-07-03 | Smithkline Beecham Laboratoires Pharmaceutiques, | Pharmaceutical formulations comprising amoxycillin and clavulanate |
| JP2000006528A (ja) * | 1998-06-25 | 2000-01-11 | Fuji Photo Film Co Ltd | 感熱記録材料 |
| US6048680A (en) * | 1998-12-09 | 2000-04-11 | Eastman Kodak Company | Photographic element containing pyrazoloazole coupler and a specific anti-fading combination |
| JP2000302793A (ja) * | 1999-02-18 | 2000-10-31 | Ono Pharmaceut Co Ltd | ホスホン酸誘導体 |
| DE10121003A1 (de) * | 2001-04-28 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
| WO2003043624A1 (en) * | 2001-11-16 | 2003-05-30 | Bristol-Myers Squibb Company | Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein |
| US7119120B2 (en) * | 2001-12-26 | 2006-10-10 | Genzyme Corporation | Phosphate transport inhibitors |
| AU2003215110B2 (en) * | 2002-02-07 | 2007-11-29 | Pharmacia Corporation | Pharmaceutical dosage form for mucosal delivery |
| AU2003258491A1 (en) * | 2002-09-05 | 2004-03-29 | Neurosearch A/S | Amide derivatives and their use as chloride channel blockers |
| US7229966B2 (en) * | 2002-12-17 | 2007-06-12 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity |
| CA2514563A1 (en) * | 2003-01-29 | 2004-08-19 | Panacos Pharmaceuticals, Inc. | Inhibition of hiv-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein |
| DE602006003661D1 (de) * | 2005-06-06 | 2008-12-24 | Lilly Co Eli | Ampa-rezeptoren-verstärker |
| GB0526252D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| KR101433392B1 (ko) * | 2006-07-14 | 2014-08-29 | 케모센트릭스, 인크. | 트리아졸릴 페닐 벤젠설폰아마이드 |
| PT2054051E (pt) * | 2006-08-16 | 2013-04-03 | Amderma Pharmaceuticals Llc | Utilização de derivados 2,5-di-hidroxibenzeno para tratar ceratose actínica |
-
2009
- 2009-07-07 CN CN200980135092.1A patent/CN102395270B/zh not_active Expired - Fee Related
- 2009-07-07 WO PCT/US2009/049744 patent/WO2010005922A1/en not_active Ceased
- 2009-07-07 MX MX2011000051A patent/MX2011000051A/es unknown
- 2009-07-07 EP EP09795032A patent/EP2303013A1/en not_active Withdrawn
- 2009-07-07 CA CA2729767A patent/CA2729767A1/en not_active Abandoned
- 2009-07-07 JP JP2011517507A patent/JP2011527345A/ja active Pending
-
2011
- 2011-10-14 US US13/273,740 patent/US20120083471A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010005922A1 (en) | 2010-01-14 |
| JP2011527345A (ja) | 2011-10-27 |
| CN102395270B (zh) | 2014-11-12 |
| US20120083471A1 (en) | 2012-04-05 |
| CN102395270A (zh) | 2012-03-28 |
| EP2303013A1 (en) | 2011-04-06 |
| MX2011000051A (es) | 2011-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2729767A1 (en) | Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same | |
| CA2735478C (en) | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators | |
| BRPI0707957A2 (pt) | composto, e, método para prevenção ou tratamento de uma condição ou sintoma patológico em um mamìfero | |
| JP5509080B2 (ja) | 抗インフルエンザ活性を有するオセルタミビル含有ホスホネートコンジナーの合成 | |
| JP4503232B2 (ja) | マロニル−ＣｏＡ脱炭酸酵素阻害剤を用いた疾患の治療法 | |
| Li et al. | Sphingosine-1-phosphate receptor 3 signaling | |
| Festuccia et al. | The PPARγ agonist rosiglitazone enhances rat brown adipose tissue lipogenesis from glucose without altering glucose uptake | |
| KR20080086546A (ko) | 신경병증성 통증의 치료 방법 | |
| WO1996015100A1 (en) | Heterocyclic compounds, their preparation and use | |
| WO2008014286A1 (en) | Vinyl phosphonate lysophosphatidic acid receptor antagonists | |
| Shiohara et al. | Discovery of novel indane derivatives as liver-selective thyroid hormone receptor β (TRβ) agonists for the treatment of dyslipidemia | |
| CA2371910A1 (en) | Inhibitors of intestinal apical membrane na/phosphate co-transportation | |
| CA3036765A1 (en) | N-methyl-d-aspartate receptor allosteric modulators and methods for their use | |
| US4973576A (en) | Bisphophonic acid derivatives and pharmaceutical compositions containing the same | |
| WO2000050390A1 (en) | N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of c-proteinase and for treating or preventing disorders related to unregulated collagen production | |
| BR112014019402B1 (pt) | Composto 2-aril-benzofuran-7-carboxamida, ou sal farmacologicamente aceitável do mesmo e método para a preparação do composto | |
| Li et al. | Pathophysiology of hepatic Na+/H+ exchange | |
| ES2955462T3 (es) | Nuevos tiromiméticos con un esqueleto de bifenilmetano y su uso | |
| AU2006252540A1 (en) | MAO-B inhibitors useful for treating obesity | |
| JP2005522509A (ja) | アシル補酵素−ａミミックとしての官能基化された長鎖誘導体、その組成物、ならびにコレステロール管理の方法および関連の使用 | |
| AU2006265639A1 (en) | MAO-B inhibitors useful for treating obesity | |
| US5304548A (en) | Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol | |
| EP3801491A1 (en) | Oleic acid derivatives, pharmaceutical composition or food composition comprising said oleic acid derivatives, and their uses | |
| CA2977001C (en) | Phosphate management with small molecules | |
| JAITRONG et al. | DESIGN AND SYNTHESIS OF BERBERINE DERIVATIVES AS PCSK9 INHIBITORFOR LIPID REDUCTION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140703 |
|
| FZDE | Dead |
Effective date: 20160707 |